Brief: Grand Pharmaceutical Says First Adjustable Intracranial Stent Retriever Product Produced In China Of Group Approved For Commercialization By NMPA
22/10/2024 15:54
Oct 22 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* FIRST ADJUSTABLE INTRACRANIAL STENT RETRIEVER PRODUCT
PRODUCED
IN CHINA OF GROUP WAS APPROVED FOR COMMERCIALIZATION BY NMPA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement